Neuroleptic Malignant Syndrome

• Dopamine antagonism in thermoregulation: Antipsychotics block D2 dopamine receptors in the hypothalamus, disrupting the hypothalamic thermoregulatory set point and impairing heat dissipation mechanisms. This leads to uncontrolled thermogenesis and inability to maintain normothermia, resulting in hyperthermia that may exceed 40°C.

• Basal ganglia dopamine depletion: Dopamine blockade in the nigrostriatal pathway causes acute dopamine depletion, leading to profound muscle rigidity (uniform, "lead pipe" rigidity throughout movement). The loss of dopaminergic inhibition of motor neurons results in unopposed gamma motor neuron activity and increased muscle tone independent of voluntary movement.

• Autonomic dysregulation: Dopamine depletion in the hypothalamus and brainstem disrupts autonomic control centers, leading to sympathetic hyperactivity manifested as tachycardia, hypertension, tachypnea, and profuse diaphoresis. Altered catecholamine metabolism and impaired sweating mechanisms contribute to uncontrolled hyperthermia despite increased metabolic rate.

• Altered mental status mechanism: Dopamine antagonism in the prefrontal cortex and limbic structures, combined with secondary effects of severe hyperthermia and metabolic derangements, causes delirium, confusion, and alterations in consciousness ranging from lethargy to catatonia.

• Muscle breakdown and rhabdomyolysis: Severe muscle rigidity combined with hyperthermia leads to excessive heat generation and muscle damage, releasing myoglobin and intracellular contents into the bloodstream. This triggers acute kidney injury (AKI) through myoglobinuric precipitation in renal tubules.

• Genetic predisposition theory: Some evidence suggests polymorphisms in dopamine D2 receptor genes and cytochrome P450 genes (CYP2D6) may increase susceptibility, explaining the idiosyncratic nature of NMS and why only a minority of exposed patients develop syndrome.

Pharmaceutical causes

• Typical antipsychotics: Haloperidol (highest risk), chlorpromazine, fluphenazine, perphenazine
• Atypical antipsychotics: Risperidone, olanzapine, quetiapine, aripiprazole (lower risk but reported)
• Antiemetics: Metoclopramide, prochlorperazine (dopamine antagonists with potential for NMS)
• Other medications: Lithium (unknown mechanism, possible synergy), SSRIs (rare, typically in combination with other agents)

Patient risk factors

• Male sex: 2-3 times higher incidence than females
• Age: Young to middle-aged adults (peak 20-40 years)
• Agitation or psychomotor hyperactivity: Baseline hyperactivity increases risk
• Previous NMS episode: 30% recurrence risk if antipsychotic reexposure occurs
• Organic brain disease: Dementia, Parkinson's disease, CNS infection increase susceptibility
• Dehydration and electrolyte abnormalities: Reduced cerebral blood flow and metabolic stress
• High ambient temperature: Environmental heat exacerbates thermoregulatory dysfunction
• High antipsychotic doses and rapid dose escalation: Risk proportional to dopaminergic blockade intensity
• Recent antipsychotic initiation: Most cases occur within first 2 weeks, but can develop at any time during treatment
• Concurrent medications: Lithium, anticholinergics (paradoxically worsen outcomes by impairing heat dissipation)

Cardinal features (tetrad)

• Hyperthermia: Temperature typically >38.5°C (often >40°C), unresponsive to antipyretics
• Rigidity: Lead pipe rigidity (uniform resistance throughout range of motion), affecting all muscle groups including jaw, neck, and trunk
• Altered mental status: Confusion, delirium, obtundation, mutism, or catatonia (ranges from mild agitation to coma)
• Autonomic instability: Tachycardia (often >100 bpm), hypertension (both systolic and diastolic), tachypnea

Additional neurological findings

• Tremor (coarse, high-amplitude, occasionally present)
• Dystonia (jaw clenching, oculogyric crisis, opisthotonus in severe cases)
• Seizures (uncommon but possible, typically late manifestation)
• Hyperreflexia and Babinski signs (reflect underlying CNS dysfunction)
• Muteness or difficulty speaking (motor speech difficulty)

Autonomic symptoms

• Profuse diaphoresis (distinctive finding; patient appears "soaked" in sweat)
• Pallor alternating with flushing
• Incontinence (urinary and/or fecal, indicates severe autonomic dysregulation)
• Tachypnea and occasional irregular breathing patterns

Laboratory/imaging correlates

• Dark, cola-colored or tea-colored urine (myoglobinuria)
• Muscular pain and tenderness on palpation
• Skin blanching over rigidic muscles (local ischemia from sustained contraction)

Time course

• Onset: Typically 24 hours to 2 weeks after antipsychotic initiation, but can occur at any point
• Duration: Average 7-10 days with treatment; up to 2-3 weeks if anticholinergic effects prolong course
• Progression: Often rapid deterioration once symptoms begin; can become life-threatening within 24-48 hours

Diagnostic criteria (DSM-5 and modification of Levenson criteria - most widely used)

1. 1.Exposure to dopamine antagonist or dopamine agonist withdrawal within 72 hours before symptom onset
2. 2.Hyperthermia (≥38.5°C/101.3°F)
3. 3.Muscle rigidity (lead pipe quality)
4. 4.Altered mental status (confusion, delirium, catatonia)

• Diaphoresis
• Tremor
• Incontinence
• Dysphagia
• Hyperreflexia/Babinski sign
• Seizure activity
• Elevated creatine kinase (CK)

Laboratory investigations

• Serum creatine kinase (CK): Most sensitive marker; typically 1,000-15,000 IU/L (can exceed 100,000 IU/L). CK elevation reflects muscle damage and correlates with severity. MB isoenzyme usually normal (distinguishes from myocardial infarction).

• Complete metabolic panel:
• Elevated creatinine and blood urea nitrogen (BUN): Indicates acute kidney injury from myoglobinuric precipitation
• BUN:creatinine ratio >20:1 suggests prerenal azotemia from dehydration
• Hyperkalemia (from rhabdomyolysis and AKI)
• Hypocalcemia (from hyperphosphatemia binding calcium)
• Elevated phosphate and uric acid (from cell breakdown)

• Complete blood count:
• Leukocytosis (WBC typically 10,000-20,000/μL); left shift with immature forms
• Hemoglobin may be elevated due to dehydration

• Coagulation studies: PT/INR, aPTT (disseminated intravascular coagulation possible in severe cases)

• Liver function tests: Elevated transaminases (ALT>AST) from heat-induced hepatocyte injury

• Urinalysis with microscopy:
• Dark/cola-colored urine (myoglobinuria)
• Positive dipstick for blood without RBCs on microscopy (myoglobin triggers peroxidase reaction)
• Brown granular casts (myoglobin casts)

• Serum iron and ferritin: Elevated (released from damaged muscle)

• Blood gas analysis: Respiratory alkalosis (from tachypnea) or metabolic acidosis (severe cases with tissue hypoxia)

• Lumbar puncture (when indicated): Cerebrospinal fluid typically normal; performed to exclude meningitis/encephalitis when diagnosis uncertain

Imaging studies

• Brain MRI/CT: Usually normal; obtained to exclude other CNS pathology if diagnosis unclear or atypical presentation
• May show nonspecific T2 hyperintensities in severe cases with prolonged hyperthermia
• Rules out hemorrhage, infarction, infection

• Muscle imaging (MRI or ultrasound): Not routine; may show edema in severely affected muscles

• Cardiac imaging:
• ECG: Sinus tachycardia, nonspecific ST-T wave changes, U waves (hypokalemia)
• Echocardiogram: Not routine; normal in uncomplicated NMS

Differential diagnosis exclusion

• Sepsis/infection: Blood cultures, chest X-ray, urinalysis
• Malignant hyperthermia: Absent in NMS; associated with anesthesia exposure and genetic predisposition
• Serotonin syndrome: History of SSRI/MAOI use; hyperreflexia and clonus predominate over rigidity; pupils dilated; GI symptoms prominent
• Anticholinergic toxidrome: Dry skin (vs. diaphoresis), dilated pupils, absent bowel sounds
• Thyroid storm: History of thyroid disease; elevated thyroid hormones; warm, moist skin but absence of rigidity
• Heat stroke: Environmental heat exposure; lack of rigidity; normal CK initially
• Encephalitis/meningitis: Meningeal signs, CSF pleocytosis, positive cultures

Immediate management (in all suspected cases)

1. 1.Discontinue the offending dopamine antagonist immediately: This is the most critical intervention and must be done without delay. No gradual tapering; abrupt cessation is appropriate.

1. 1.Aggressive supportive care (foundation of treatment):

• Cooling measures:
• Ice packs to groin, axillae, neck (areas of major vessel proximity)
• Tepid water sponging
• Cooling blankets
• Cold intravenous saline (goal: reduce temperature to <38.5°C)
• Intubation and paralysis (permits evaporative cooling if severe)
• Hydration:
• Aggressive IV crystalloid (normal saline or lactated Ringer's) at 200-300 mL/hr initially
• Goal: Maintain urine output 200-300 mL/hr to prevent myoglobin precipitation
• Insert Foley catheter for accurate monitoring
• May require 5-10 L or more in first 24 hours
• Electrolyte correction:
• Potassium replacement if <5.0 mEq/L (monitor closely; hyperkalemia more common initially)
• Calcium gluconate if serum potassium >6.5 mEq/L with ECG changes
• Sodium bicarbonate (IV 50-100 mEq bolus) to alkalinize urine (increases myoglobin solubility and reduces precipitation)

1. 1.Continuous monitoring:

• Vital signs every 15-30 minutes initially
• Continuous cardiac monitoring (watch for arrhythmias from hyperkalemia)
• Foley catheter with strict intake/output monitoring
• Core temperature monitoring (esophageal probe preferred for accuracy)

First-line pharmacological treatment

• Dantrolene sodium: Gold standard pharmacotherapy for NMS
• Mechanism: Direct skeletal muscle relaxant; inhibits calcium release from sarcoplasmic reticulum via ryanodine receptor antagonism, reducing muscle contractility and heat generation
• Dosing: 2.5 mg/kg IV bolus, may repeat every 5-10 minutes up to maximum 10 mg/kg or until symptoms resolve
• Typical cumulative dose: 5-10 mg/kg total
• Maintenance (if needed): 1 mg/kg IV qid for 24-48 hours after last dose elevation; PO 5 mg/kg/day in divided doses for 5-7 days
• Mechanism of action in NMS: Reduces muscle rigidity, decreases heat production, prevents rhabdomyolysis progression
• Efficacy: Reduces mortality from ~20% to ~5% when used promptly
• Side effects: Hepatotoxicity (obtain baseline LFTs; monitor weekly during prolonged use), weakness, phlebitis at infusion site, nausea
• Monitoring: Liver function tests at baseline and weekly if prolonged therapy; watch for hepatic dysfunction
• Preparation: Requires reconstitution with sterile water immediately before use (degrades rapidly); requires large-bore IV access

• Bromocriptine mesylate: Dopamine D2 receptor agonist (alternative or adjunctive)
• Mechanism: Directly stimulates dopamine receptors to counteract dopamine antagonist effects; increases central dopaminergic activity
• Dosing: 2.5-5 mg PO three times daily (or NG tube if unable to swallow)
• Duration: Continue 5-7 days after normalization of symptoms
• Onset: Slower than dantrolene (hours to days)
• Efficacy: Comparable to dantrolene in some series; often combined with dantrolene for synergistic effect
• Side effects: Nausea, vomiting, orthostatic hypotension, agitation
• Advantage: Orally available; addresses underlying dopamine depletion
• Disadvantage: Slower onset; less effective for rigidity compared to dantrolene

Second-line therapies

• Amantadine: Dopamine agonist and NMDA receptor antagonist
• Dosing: 100 mg IV or PO three times daily
• Less proven than dantrolene/bromocriptine but may provide adjunctive benefit
• Mechanism unclear but may enhance dopaminergic transmission

• Lorazepam: Benzodiazepine for agitation, seizure prophylaxis
• Dosing: 1-2 mg IV/IM every 4-6 hours as needed
• Does not address underlying NMS pathophysiology but provides symptom control
• Avoid in respiratory compromise

• Levodopa (rarely used): May enhance dopamine activity in severe cases refractory to other measures

Non-pharmacological measures

• Maintain NPO status initially (aspiration risk with altered mental status)
• Nasogastric tube for nutrition if prolonged course
• Mechanical ventilation and paralysis if needed for:
• Severe hyperthermia unresponsive to cooling
• Respiratory compromise
• Ability to perform aggressive cooling
• Severe rhabdomyolysis complications

• Physical therapy and passive range of motion once acute phase resolves

Monitoring during acute phase

• Repeat laboratory values every 4-6 hours initially:
• CK, creatinine, potassium, phosphate, calcium
• Urinalysis (watch for clearing of myoglobinuria)
• Goal CK <5,000 IU/L before discharge

• Continue aggressive hydration until:
• Urine becomes clear
• CK normalizes or plateaus
• Renal function stabilizes
• Usually 3-5 days

• Monitor for complications (see Complications section)

Disease-related — emergencies

• Myoglobinuric acute kidney injury: sustained rigidity plus hyperthermia lyses myocytes; filtered myoglobin precipitates with Tamm-Horsfall protein and causes direct tubular toxicity and vasoconstriction. Signaled by rising creatinine with cola-colored urine and dipstick blood without RBCs. Emergency — KDIGO AKI guidance supports early volume expansion and prompt nephrology involvement for refractory hyperkalemia, acidosis, or volume overload requiring renal replacement therapy.
• Hyperkalemic arrhythmia: intracellular potassium released from necrotic muscle, compounded by oliguria. Signaled by peaked T waves, then QRS widening on the monitor; treat per AHA/ACLS hyperkalemia sequence (calcium for membrane stabilization, insulin/dextrose, then removal).
• Respiratory failure: chest wall and diaphragmatic rigidity restrict ventilation while metabolic demand soars; hypercapnia and aspiration from impaired swallowing/obtundation are the usual triggers. Emergency — low threshold for intubation.
• Venous thromboembolism: immobility, dehydration, and an acute-phase state; sudden hypoxemia or pleuritic pain in a recovering patient. Pulmonary embolism is a recognized cause of NMS mortality — use pharmacologic prophylaxis unless contraindicated.
• Disseminated intravascular coagulation and hepatic injury: heat-mediated endothelial and hepatocyte damage; signaled by falling platelets, rising INR, oozing from IV sites.
• Compartment syndrome: swelling within rigid fascial compartments after massive rhabdomyolysis; disproportionate pain and pain on passive stretch. Emergency — fasciotomy.

Late/residual

• Persistent catatonia or parkinsonism: may outlast the acute episode by weeks, particularly after depot antipsychotics.
• Recurrence on rechallenge: significant risk; APA schizophrenia guidance advises waiting until full resolution, then reintroducing a lower-potency or second-generation agent at low dose with close monitoring.

Treatment-related

• Dantrolene hepatotoxicity: dose- and duration-dependent; follow transaminases. Also causes generalized weakness that can blunt respiratory effort.
• Bromocriptine effects: dopaminergic agonism can worsen psychosis and cause orthostatic hypotension and vomiting.
• Over-resuscitation/alkalinization: pulmonary edema, and bicarbonate-induced hypocalcemia worsening tetany.
• Abrupt antipsychotic withdrawal: psychiatric decompensation — necessary, but anticipate it.

• The stem signature: a young agitated man started on haloperidol (or given metoclopramide) days ago, now with lead-pipe rigidity, temperature >40°C, delirium, drenching diaphoresis, and a markedly elevated CK with leukocytosis. Rigidity is uniform and generalized — not cogwheeling, not clonus.
• Single best next step: stop the dopamine antagonist and begin aggressive supportive care (cooling, IV crystalloid to protect the kidneys). Examiners reward "discontinue the offending agent" over "give dantrolene" — pharmacotherapy is adjunctive to stopping the drug and resuscitating.
• Serotonin syndrome is the money distractor: onset in hours rather than days, clonus and hyperreflexia (lower extremities > upper), mydriasis, diarrhea, and hyperactive bowel sounds; antidote is a serotonin antagonist (cyproheptadine). NMS is bradykinetic and hyporeflexic-appearing with rigidity.
• Malignant hyperthermia is the other: triggered intraoperatively by succinylcholine or volatile anesthetics via a RYR1 mutation, with masseter spasm and a rapidly rising end-tidal CO₂. Dantrolene treats both, which is why sharing the drug does not make them the same disease.
• The association examiners love: abrupt withdrawal of levodopa or a dopamine agonist in Parkinson disease produces an identical picture (parkinsonism-hyperpyrexia syndrome) — the answer is to restart the dopaminergic agent, not to add a new drug.
• Urine dipstick positive for blood with no RBCs on microscopy = myoglobinuria. Pair it with CK to confirm rhabdomyolysis.
• Refractory or catatonia-predominant cases: electroconvulsive therapy is the accepted rescue, consistent with APA guidance on catatonia and NMS.
• Rechallenge: after full recovery, an atypical antipsychotic at low dose with slow titration; recurrence risk is substantial, and depot formulations should be avoided. Avoid anticholinergics (they impair sweating) and avoid succinylcholine in established rhabdomyolysis (hyperkalemia).